Trial Profile

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Sep 2020 Results of three phase1, first-in-human studies (NCT03311412, NCT03489369; NCT03489343) assessing effect Sym021, Sym022, and Sym023 alone and Sym021 in combination with either Sym022 or Sym023, presented at the 45th European Society for Medical Oncology Congress.
08 Sep 2020 Status changed from active, no longer recruiting to completed.
09 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com